FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107691259> ?p ?o ?g. }

• W2107691259 endingPage "2255" @default.
• W2107691259 startingPage "2244" @default.
• W2107691259 abstract "Sublingual buprenorphine and combination buprenorphine/naloxone (BNX) are effective options for the treatment of opioid dependence. A BNX sublingual tablet approved by the US Food and Drug Administration for the induction and maintenance treatment of opioid-dependence in adults was developed as a higher-bioavailability formulation, allowing for a 30% lesser dose of buprenorphine with bioequivalent systemic exposure compared with another BNX sublingual tablet formulation. No data were previously available comparing the higher-bioavailability BNX sublingual tablet to generic buprenorphine or BNX sublingual film; we therefore evaluated treatment retention during induction and stabilization with the higher-bioavailability BNX sublingual tablet versus generic buprenorphine or BNX sublingual film.This multicenter, prospective, randomized, parallel-group noninferiority trial was conducted at 43 centers in the United States. Eligible patients were adults aged 18 to 65 years who met the criteria for opioid dependence and had at least mild withdrawal symptoms. On days 1 and 2, patients received blinded, fixed-dose induction with the higher-bioavailability BNX sublingual tablet or generic buprenorphine. On days 3 to 14, patients induced with BNX received open-label, titrated doses of the BNX tablet for stabilization; patients induced with buprenorphine received sublingual BNX film. Co-primary end points were treatment retention on days 3 and 15; noninferiority was concluded if the lower limit of the 95% CI of the between-group difference in treatment retention was ≥-10%. Tolerability was assessed throughout the study period.A total of 758 opioid-dependent patients were included in the study (BNX sublingual tablet, 383 patients; generic buprenorphine, 375). Day-3 retention rates were 93.9% (309/329) and 92.6% (302/326) with the BNX tablet and buprenorphine, respectively (between-group difference 95% CI, -2.6 to 5.1). Day-15 retention rates were 83.0% (273/329) and 82.5% (269/326) with the BNX tablet and BNX film, respectively (between-group difference 95% CI, -5.3 to 6.3). No unexpected tolerability issues were identified; the safety profile of the BNX sublingual tablet was similar to those of generic buprenorphine and BNX film.Based on the findings from this study in patients with opioid dependence, the higher-bioavailability BNX sublingual tablet formulation was noninferior to both generic buprenorphine (induction) and BNX film (stabilization). These findings suggest that BNX sublingual tablets are an efficacious and well-tolerated option for induction and early stabilization treatment of opioid dependence. ClinicalTrials.gov identifier: NCT01908842." @default.
• W2107691259 created "2016-06-24" @default.
• W2107691259 creator A5023038090 @default.
• W2107691259 creator A5052709597 @default.
• W2107691259 creator A5077485223 @default.
• W2107691259 date "2015-10-01" @default.
• W2107691259 modified "2023-10-17" @default.
• W2107691259 title "Effects of a Higher-bioavailability Buprenorphine/Naloxone Sublingual Tablet Versus Buprenorphine/Naloxone Film for the Treatment of Opioid Dependence During Induction and Stabilization: A Multicenter, Randomized Trial" @default.
• W2107691259 cites W1600265429 @default.
• W2107691259 cites W1659527729 @default.
• W2107691259 cites W1969823428 @default.
• W2107691259 cites W1970071038 @default.
• W2107691259 cites W1976869578 @default.
• W2107691259 cites W1990596751 @default.
• W2107691259 cites W2014534410 @default.
• W2107691259 cites W2048376222 @default.
• W2107691259 cites W2060537745 @default.
• W2107691259 cites W2064271499 @default.
• W2107691259 cites W2065431063 @default.
• W2107691259 cites W2078154157 @default.
• W2107691259 cites W2088191781 @default.
• W2107691259 cites W2093376565 @default.
• W2107691259 cites W2100833669 @default.
• W2107691259 cites W2119421920 @default.
• W2107691259 cites W2160744884 @default.
• W2107691259 cites W2170421916 @default.
• W2107691259 cites W2172169298 @default.
• W2107691259 doi "https://doi.org/10.1016/j.clinthera.2015.08.025" @default.
• W2107691259 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26412801" @default.
• W2107691259 hasPublicationYear "2015" @default.
• W2107691259 type Work @default.
• W2107691259 sameAs 2107691259 @default.
• W2107691259 citedByCount "17" @default.
• W2107691259 countsByYear W21076912592016 @default.
• W2107691259 countsByYear W21076912592017 @default.
• W2107691259 countsByYear W21076912592018 @default.
• W2107691259 countsByYear W21076912592020 @default.
• W2107691259 countsByYear W21076912592022 @default.
• W2107691259 crossrefType "journal-article" @default.
• W2107691259 hasAuthorship W2107691259A5023038090 @default.
• W2107691259 hasAuthorship W2107691259A5052709597 @default.
• W2107691259 hasAuthorship W2107691259A5077485223 @default.
• W2107691259 hasBestOaLocation W21076912591 @default.
• W2107691259 hasConcept C126322002 @default.
• W2107691259 hasConcept C170493617 @default.
• W2107691259 hasConcept C181389837 @default.
• W2107691259 hasConcept C197934379 @default.
• W2107691259 hasConcept C2778375690 @default.
• W2107691259 hasConcept C2778750930 @default.
• W2107691259 hasConcept C2778949969 @default.
• W2107691259 hasConcept C2779350572 @default.
• W2107691259 hasConcept C2781063702 @default.
• W2107691259 hasConcept C42219234 @default.
• W2107691259 hasConcept C42404028 @default.
• W2107691259 hasConcept C71924100 @default.
• W2107691259 hasConcept C98274493 @default.
• W2107691259 hasConceptScore W2107691259C126322002 @default.
• W2107691259 hasConceptScore W2107691259C170493617 @default.
• W2107691259 hasConceptScore W2107691259C181389837 @default.
• W2107691259 hasConceptScore W2107691259C197934379 @default.
• W2107691259 hasConceptScore W2107691259C2778375690 @default.
• W2107691259 hasConceptScore W2107691259C2778750930 @default.
• W2107691259 hasConceptScore W2107691259C2778949969 @default.
• W2107691259 hasConceptScore W2107691259C2779350572 @default.
• W2107691259 hasConceptScore W2107691259C2781063702 @default.
• W2107691259 hasConceptScore W2107691259C42219234 @default.
• W2107691259 hasConceptScore W2107691259C42404028 @default.
• W2107691259 hasConceptScore W2107691259C71924100 @default.
• W2107691259 hasConceptScore W2107691259C98274493 @default.
• W2107691259 hasIssue "10" @default.
• W2107691259 hasLocation W21076912591 @default.
• W2107691259 hasLocation W21076912592 @default.
• W2107691259 hasOpenAccess W2107691259 @default.
• W2107691259 hasPrimaryLocation W21076912591 @default.
• W2107691259 hasRelatedWork W1978978867 @default.
• W2107691259 hasRelatedWork W1979600943 @default.
• W2107691259 hasRelatedWork W1990071324 @default.
• W2107691259 hasRelatedWork W2035750389 @default.
• W2107691259 hasRelatedWork W2134002187 @default.
• W2107691259 hasRelatedWork W2159281741 @default.
• W2107691259 hasRelatedWork W2171498933 @default.
• W2107691259 hasRelatedWork W2461265123 @default.
• W2107691259 hasRelatedWork W2768491337 @default.
• W2107691259 hasRelatedWork W3037586716 @default.
• W2107691259 hasVolume "37" @default.
• W2107691259 isParatext "false" @default.
• W2107691259 isRetracted "false" @default.
• W2107691259 magId "2107691259" @default.
• W2107691259 workType "article" @default.